Yan Wang1,2, Qiong Lei1,3,4, Cangjie Shen1, Nan Wang5. 1. Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, 1st, Xiannongtan Street, Xicheng District, Beijing, 100050, People's Republic of China. 2. Department of Medicine, Open University of China, Beijing, People's Republic of China. 3. Department of Pharmacology, Gannan Medical College, Jiangxi Province, Ganzhou, People's Republic of China. 4. Ningbo Clinicopathologic Diagnosis Center, Zhejiang Province, Ningbo, People's Republic of China. 5. Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, 1st, Xiannongtan Street, Xicheng District, Beijing, 100050, People's Republic of China. wangnan@imm.ac.cn.
Abstract
PURPOSE: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) binds to death receptor (DR) 4 and DR5 and induces tumor-selective apoptosis. The fusion proteins NCTR25-TRAIL and NCTR25-TGF3L-TRAIL self-assembled into polymers and triggered super-active cancer cell killing. The role of TGF3L in self-assembly and super-activity was unclear. These multivalent TRAILs elicited apoptosis with great potency, but their specificity towards receptors and subsequent efficacy in signal activation were unclear. METHODS: NCTR25-TRAIL fusion was constructed and prokaryotically expressed. The size of fusion protein polymers was estimated. Their cytotoxicity was assessed in eight cancer cell lines and two noncancerous cell lines. Receptor binding and activation specificity were determined by antibody blockade. Apoptosis was evaluated, and the associated pathway was verified by quantifying caspase activity. The NF-κB signaling pathway was assessed by dual-luciferase assay. The in vivo antitumor activity was also evaluated in nude mice. RESULTS: NCTR25 fusion to TRAIL promoted its self-assembly into polymers and showed similar super-cytotoxicity to NCTR25-TGF3L-TRAIL in vitro. The multivalent TRAILs exclusively activated both DR4 and DR5 and showed a bias towards DR4 in mediating cytotoxicity in NCI-H460 cells. They activated caspase pathway and induced apoptosis with higher potency but in similar efficacy than TRAIL. A higher potency and a greater efficacy were observed in activating NF-κB pathway by NCTR25-TRAIL comparing to TRAIL. Both the polymers showed better in vivo antitumor activity than TRAIL. CONCLUSIONS: NCTR25 fusion alone facilitates the formation of TRAIL polymers. Multivalent TRAIL polymers bind and activate DR4 and DR5 specifically and exclusively, triggering the signaling pathways with higher potency, and greater efficacy than TRAIL.
PURPOSE:Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) binds to death receptor (DR) 4 and DR5 and induces tumor-selective apoptosis. The fusion proteins NCTR25-TRAIL and NCTR25-TGF3L-TRAIL self-assembled into polymers and triggered super-active cancer cell killing. The role of TGF3L in self-assembly and super-activity was unclear. These multivalent TRAILs elicited apoptosis with great potency, but their specificity towards receptors and subsequent efficacy in signal activation were unclear. METHODS: NCTR25-TRAIL fusion was constructed and prokaryotically expressed. The size of fusion protein polymers was estimated. Their cytotoxicity was assessed in eight cancer cell lines and two noncancerous cell lines. Receptor binding and activation specificity were determined by antibody blockade. Apoptosis was evaluated, and the associated pathway was verified by quantifying caspase activity. The NF-κB signaling pathway was assessed by dual-luciferase assay. The in vivo antitumor activity was also evaluated in nude mice. RESULTS: NCTR25 fusion to TRAIL promoted its self-assembly into polymers and showed similar super-cytotoxicity to NCTR25-TGF3L-TRAIL in vitro. The multivalent TRAILs exclusively activated both DR4 and DR5 and showed a bias towards DR4 in mediating cytotoxicity in NCI-H460 cells. They activated caspase pathway and induced apoptosis with higher potency but in similar efficacy than TRAIL. A higher potency and a greater efficacy were observed in activating NF-κB pathway by NCTR25-TRAIL comparing to TRAIL. Both the polymers showed better in vivo antitumor activity than TRAIL. CONCLUSIONS: NCTR25 fusion alone facilitates the formation of TRAILpolymers. Multivalent TRAILpolymers bind and activate DR4 and DR5 specifically and exclusively, triggering the signaling pathways with higher potency, and greater efficacy than TRAIL.
Entities:
Keywords:
Death receptors; Efficacy; Polymer; Potency; TRAIL
Authors: F Mühlenbeck; P Schneider; J L Bodmer; R Schwenzer; A Hauser; G Schubert; P Scheurich; D Moosmayer; J Tschopp; H Wajant Journal: J Biol Chem Date: 2000-10-13 Impact factor: 5.157
Authors: Jonathan D Graves; Jennifer J Kordich; Tzu-Hsuan Huang; Julia Piasecki; Tammy L Bush; Timothy Sullivan; Ian N Foltz; Wesley Chang; Heather Douangpanya; Thu Dang; Jason W O'Neill; Rommel Mallari; Xiaoning Zhao; Daniel G Branstetter; John M Rossi; Alexander M Long; Xin Huang; Pamela M Holland Journal: Cancer Cell Date: 2014-07-17 Impact factor: 31.743
Authors: Diego De Miguel; Ana Gallego-Lleyda; José María Ayuso; Dolores Pejenaute-Ochoa; Vidal Jarauta; Isabel Marzo; Luis J Fernández; Ignacio Ochoa; Blanca Conde; Alberto Anel; Luis Martinez-Lostao Journal: Cancer Lett Date: 2016-10-08 Impact factor: 8.679
Authors: Christian Gieffers; Michael Kluge; Christian Merz; Jaromir Sykora; Meinolf Thiemann; René Schaal; Carmen Fischer; Marcus Branschädel; Behnaz Ahangarian Abhari; Peter Hohenberger; Simone Fulda; Harald Fricke; Oliver Hill Journal: Mol Cancer Ther Date: 2013-10-07 Impact factor: 6.261
Authors: Anne V Yagolovich; Artem A Artykov; Alina A Isakova; Yekaterina V Vorontsova; Dmitry A Dolgikh; Mikhail P Kirpichnikov; Marine E Gasparian Journal: Int J Mol Sci Date: 2022-05-24 Impact factor: 6.208